Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 5/20 | 0.36 |
| ▸ | SMO | Q99835 | 5/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8318641 | 0.89 | NCF1 (0.41) | NCF1NSD2ACHESMOALDH1A1 | |
| SCHEMBL29252437 | 0.83 | NCF1 (0.45) | NCF1NSD2ACHEGNAI3GNAO1 | |
| SCHEMBL12593545 | 0.80 | NCF1 (0.46) | NCF1NSD2ACHEGNAI3GNAO1 | |
| SCHEMBL1273104 | 0.80 | TP53 (0.48) | ALDH1A1 | |
| SCHEMBL20744331 | 0.80 | NCF1 (0.52) | NCF1NSD2ACHESMOGNAI3 | |
| SCHEMBL19734284 | 0.80 | NCF1 (0.46) | NCF1NSD2ACHEGNAI3GNAO1 | |
| SCHEMBL16907705 | 0.80 | SMO (0.35) | SMORORCALDH1A1 | |
| SCHEMBL1272565 | 0.80 | — | — | |
| SCHEMBL1272200 | 0.78 | SMN1; SMN2 (0.42) | SMOHRH3RORC | |
| Hydrochloric Acid SCHEMBL4874119 | 0.78 | INPP5A (0.47) | NCF1NSD2ACHEGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082786-B1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021018195-A1 | NOVEL TRICYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-02-04 | — | — | WO | disclosed |
| EP-3172214-B1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20180072732-A1 | 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-03-15 | — | — | US | disclosed |
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9751873-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8404708-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404708-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2011-07-21 | — | — | US | disclosed |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2011-07-21 | — | — | US | disclosed |
| US-7939533-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939533-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | GPR119, GPR65, GPR55 | NCF1 3450/4885NSD2 3840/4885ACHE 3870/4885 |
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | NCF1 2349/4885NSD2 3880/4885ACHE 2859/4885 |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | NCF1 2189/4885NSD2 1012/4885ACHE 3236/4885 |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | TACR2, TAC3, TACR1 | NCF1 1090/4885NSD2 2729/4885ACHE 3263/4885 |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | NCF1 2171/4885NSD2 1018/4885ACHE 3312/4885 |
| US-20180072732-A1 | 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | PIK3CA, AKT3, AKT2 | NCF1 1647/4885NSD2 1086/4885ACHE 3163/4885 |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | NCF1 2349/4885NSD2 3880/4885ACHE 2859/4885 |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | TACR2, TAC3, TACR1 | NCF1 1090/4885NSD2 2729/4885ACHE 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.